DE

566.64

+1.89%↑

FDX

363.83

+4.78%↑

HEICO

276.98

+3.56%↑

HEICA

211.96

+2.87%↑

CPRT

33.12

+1.22%↑

DE

566.64

+1.89%↑

FDX

363.83

+4.78%↑

HEICO

276.98

+3.56%↑

HEICA

211.96

+2.87%↑

CPRT

33.12

+1.22%↑

DE

566.64

+1.89%↑

FDX

363.83

+4.78%↑

HEICO

276.98

+3.56%↑

HEICA

211.96

+2.87%↑

CPRT

33.12

+1.22%↑

DE

566.64

+1.89%↑

FDX

363.83

+4.78%↑

HEICO

276.98

+3.56%↑

HEICA

211.96

+2.87%↑

CPRT

33.12

+1.22%↑

DE

566.64

+1.89%↑

FDX

363.83

+4.78%↑

HEICO

276.98

+3.56%↑

HEICA

211.96

+2.87%↑

CPRT

33.12

+1.22%↑

Search

Apogee Enterprises Inc

Atidarymo kaina

SektoriusPramonės sektorius

33.4 1.92

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

32.23

Max

33.55

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-7.1M

17M

Pardavimai

-9.6M

349M

P/E

Sektoriaus vid.

17.348

51.05

Dividendų pajamingumas

3.2

Pelno marža

4.748

Darbuotojai

4,500

EBITDA

-3.8M

41M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+38.72% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.20%

2.30%

Kitas uždarbis

2026-04-23

Kitas dividendų mokėjimo data

2026-05-27

Kita Ex Dividend data

2026-05-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-102M

698M

Ankstesnė atidarymo kaina

31.48

Ankstesnė uždarymo kaina

33.4

Naujienos nuotaikos

By Acuity

21%

79%

47 / 405 reitingas Industrials

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Apogee Enterprises Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-31 23:31; UTC

Karštos akcijos

Stocks to Watch: Nike, RH, NCino

2026-03-31 22:35; UTC

Uždarbis

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026-04-01 00:00; UTC

Įsigijimai, susijungimai, perėmimai

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026-03-31 23:50; UTC

Įsigijimai, susijungimai, perėmimai

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026-03-31 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026-03-31 23:33; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026-03-31 23:21; UTC

Uždarbis

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026-03-31 23:14; UTC

Rinkos pokalbiai
Uždarbis

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026-03-31 23:12; UTC

Rinkos pokalbiai

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss Widens >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026-03-31 21:46; UTC

Įsigijimai, susijungimai, perėmimai

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026-03-31 21:36; UTC

Rinkos pokalbiai

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026-03-31 21:35; UTC

Uždarbis

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026-03-31 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026-03-31 21:33; UTC

Uždarbis

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026-03-31 21:32; UTC

Uždarbis

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026-03-31 21:28; UTC

Uždarbis

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026-03-31 21:26; UTC

Uždarbis

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026-03-31 21:25; UTC

Uždarbis

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026-03-31 21:24; UTC

Rinkos pokalbiai
Uždarbis

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026-03-31 21:22; UTC

Uždarbis

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026-03-31 21:22; UTC

Uždarbis

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026-03-31 21:21; UTC

Uždarbis

Nike's Digital Channel Still Too Promotional, CFO Says

2026-03-31 21:20; UTC

Uždarbis

Nike CEO: Converse Remains Important to Portfolio

Akcijų palyginimas

Kainos pokytis

Apogee Enterprises Inc Prognozė

Kainos tikslas

By TipRanks

38.72% į viršų

12 mėnesių prognozė

Vidutinis 45 USD  38.72%

Aukščiausias 46 USD

Žemiausias 44 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Apogee Enterprises Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

40.03 / 40.44Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

47 / 405 reitingas Pramonės sektorius

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Apogee Enterprises Inc

Apogee Enterprises, Inc. provides architectural products and services for enclosing buildings, and glass and acrylic products used for preservation, protection, and enhanced viewing in the United States, Canada, and Brazil. The company operates in four segments: Architectural Framing Systems, Architectural Glass, Architectural Services, and Large-Scale Optical (LSO). The Architectural Framing Systems segment designs, engineers, fabricates, finishes, and installs custom glass and aluminum window, curtainwall, storefront, and entrance systems for the exterior of buildings primarily in the non-residential construction sectors. The Architectural Glass segment provides a range of high-performance glass products for use in windows, curtainwall, storefront, and entrance systems. The Architectural Services segment integrates technical services, project management, and field installation services to design, engineer, fabricate, and install building glass and curtainwall systems. The LSO segment manufactures high-performance glazing products for the custom framing, fine art, and engineered optics markets. The company's products and services are primarily used in commercial buildings, such as office buildings, hotels, and retail centers; institutional buildings comprising education facilities, health care facilities, and government buildings; transportation facilities, such as airports and transit terminals, as well as multi-family residential buildings. It markets its architectural products and services through direct sales force, independent sales representatives, distributors, and glazing subcontractors and general contractors; and value-added glass and acrylics through retail chains, as well as independent distributors to museums, galleries, and other customers. The company was incorporated in 1949 and is based in Minneapolis, Minnesota.
help-icon Live chat